"We did not develop the cancer drug (Nexavar) for Indians. We developed it for western patients who can afford it," German drugmaker Bayer's CEO Marijn Dekkers reportedly said last month. He termed action of India's controller general of patents, who in 2012 authorized a local drugmaker to produce a low-priced and generic copy of the costly Nexavar, as "essentially theft".